文献速递胸部肿瘤

表皮生长因子受体突变肺癌的组织学转化

Histologic transformation of epidermal growth factor receptor-mutated lung cancer.
PubMed 文献 · Eur J Cancer · 2022-03-09

这项多中心回顾性队列研究纳入2012至2019年间接受EGFR-TKI治疗的晚期EGFR突变肺癌患者6356例,其中2624例在耐药后经再活检证实组织学类型,74例发生组织学转化,发生率为2.8%(95%CI 2.3%-3.5%)。确诊组织学转化后中位总生存期为12.2个月,免疫检查点抑制剂治疗后中位无进展生存期仅1.6个月。

要点

  • EGFR-TKI耐药后经再活检证实的组织学转化发生率为2.8%(95%CI 2.3%-3.5%)。
  • 确诊组织学转化后中位总生存期为12.2个月,一线治疗后中位无进展生存期为4.4个月。
  • 确诊组织学转化后接受免疫检查点抑制剂治疗的中位无进展生存期为1.6个月。

核心结论

  • 约3%的EGFR突变患者在EGFR-TKI耐药后发生组织学转化。
  • 细胞毒药物可能对组织学转化患者有效,但免疫检查点抑制剂的疗效有限。
  • 鉴于组织学转化罕见且缺乏前瞻性试验,本研究结果对指导这类患者的治疗具有重要意义。

研究设计与样本

  • 多中心、回顾性队列研究,纳入2012至2019年间接受EGFR-TKI治疗的晚期EGFR突变肺癌患者6356例。
  • 2624例患者在EGFR-TKI耐药后经再活检证实组织学类型。
  • 主要结局为组织学转化的发生率,次要结局为组织学转化患者的治疗疗效。

主要发现

  • 6356例患者中,2624例经再活检证实组织学类型,其中74例发生组织学转化,发生率为2.8%(95%CI 2.3%-3.5%)。
  • EGFR-TKI治疗后中位无进展生存期为10.4个月,确诊组织学转化后一线治疗的中位无进展生存期为4.4个月。
  • 转化为高级别神经内分泌癌与转化为其他非小细胞肺癌亚型患者之间的无进展生存期无显著差异。
  • 确诊组织学转化后中位总生存期为12.2个月。
  • 27例患者接受免疫检查点抑制剂治疗,其中6例在确诊组织学转化前、21例在确诊后接受;无患者达到1年无进展生存。

临床怎么用

  • 作者认为细胞毒药物可能对组织学转化患者有效。
  • 作者指出免疫检查点抑制剂在这类患者中的治疗有效性有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to determine the incidence and clinical course of epidermal growth factor receptor (EGFR)-mutated lung cancer with histologic transformation (HT). PATIENTS AND METHODS: We conducted a multicentre, retrospective, cohort study of patients with advanced EGFR-mutated lung cancer who received EGFR-tyrosine kinase inhibitors (TKIs) between 2012 and 2019. The primary outcome was the incidence of HT. The secondary outcome was treatment efficacy in patients with HT. RESULTS: In total, 6356 patients were enrolled. In 2624 patients, the histological type was proven by rebiopsy after acquiring resistance to EGFR-TKIs. Among them, 74 patients had HT (incidence rate: 2.8% [95% confidence interval: 2.3%-3.5%]). The median progression-free survival after EGFR-TKIs and first-line therapy after confirming HT was 10.4 and 4.4 months, respectively, which was not significantly different between patients with transformation to high-grade neuroendocrine carcinoma and those with transformation to another subtype of non-small cell lung cancer. Overall survival after confirming HT was 12.2 months. Twenty-seven patients received immune checkpoint inhibitors: 6 and 21 received immune checkpoint inhibitors before and after confirming HT, respectively. No patients achieved 1-year progression-free survival. The median progression-free survival after immune checkpoint inhibitor therapy after confirming HT was 1.6 months. CONCLUSION: HT occurred in approximately 3% of EGFR-mutated patients who developed resistance to EGFR-TKIs. Cytotoxic agents are likely to be effective in patients with HT. However, the therapeutic effectiveness of immune checkpoint inhibitors was limited in these patients. Given the rarity of HT and absence of prospective trials, our findings are important to inform the treatment of these patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fujimoto D, Akamatsu H, Morimoto T, et al. Histologic transformation of epidermal growth factor receptor-mutated lung cancer. Eur J Cancer. 2022. PMID: 35278824. doi:10.1016/j.ejca.2022.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。